Furthermore, the above strategy may also be important in the treatment of the more severe condition of NASH, since NASH patients subjected to a mixture of n-3 LCPUFAS (α-linolenic acid (ALA), EPA and DHA) for 6 months exhibit improvement of mitochondrial function with induction of the chaperone HSP60, in addition to attenuation of hepatic lipogenesis and ER stress [179]. This evidence concerns the gene HSPD1 and metabolic dysfunction-associated steatohepatitis.